Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436410 · ClinicalTrials.gov registry record · Early Phase 1
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
A Early Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 108
- Enrollment target
NCT00436410: Completed Early Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00436410 is a Early Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 108 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (104% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00436410, a Early Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing. Studying tumor necrosis factor in samples of tumor tissue and healthy tissue from patients with cancer in the laboratory may help doctors learn how tumor necrosis factor works in tumor tissue and healthy tissue. PURPOSE: This clinical trial is studying tumor necrosis factor in patients undergoing surgery for primary cancer or metastatic cancer .
Interventions
- OTHER pharmacological study
- PROCEDURE conventional surgery
- OTHER electron microscopy
- BIOLOGICAL colloidal gold-bound tumor necrosis factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-08 |
| Phase | Early Phase 1 |
What the finished NCT00436410 record still lists
NCT00436410 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (104% higher).
The record links to 0 conditions, and to 4 interventions - of which pharmacological study is the first listed.
NCT00436410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00436410 about?
NCT00436410 is a clinical study titled "Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer". RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing. Studying tumor necrosis factor in samples of tumor tissue and healthy tissue from patients with cancer in the laboratory may help doctors learn how tum...
What is the current status of trial NCT00436410?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 108 participants. The study started on 2006-12. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00436410?
The interventions under investigation include: pharmacological study (OTHER), conventional surgery (PROCEDURE), electron microscopy (OTHER), colloidal gold-bound tumor necrosis factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00436410?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00436410's enrollment target sits among peer trials
108 170th of 2000 higher than 1,828 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia